Dissolve-E: FHIR Implementation Guide for the AWMF Guideline Registry
0.1.0 - qa-preview

Dissolve-E: FHIR Implementation Guide for the AWMF Guideline Registry - Downloaded Version 0.1.0 See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 DISSOLVE-E Implementation Guide
... 2 Profiles
... 3 Extensions
... 4 Code Systems
... 5 Value Sets
... 6 Examples
... 7 Artifacts Summary
.... 7.1 AWMF Guideline
.... 7.2 AWMF Member Organization
.... 7.3 AWMF S1 Guideline
.... 7.4 AWMF S2e Guideline
.... 7.5 AWMF S2k Guideline
.... 7.6 AWMF S3 Guideline
.... 7.7 Certainty of Evidence Rating
.... 7.8 Evidence Assessment AGREE II
.... 7.9 Evidence Assessment AMSTAR 2
.... 7.10 Evidence Assessment Cochrane Risk of Bias
.... 7.11 Evidence Assessment GRADE
.... 7.12 Evidence Assessment Oxford 2011
.... 7.13 Evidence Assessment ROBIS
.... 7.14 Guideline
.... 7.15 Guideline Attachment
.... 7.16 Guideline Author
.... 7.17 Guideline Author Role
.... 7.18 Outcome Evidence
.... 7.19 Recommendation
.... 7.20 Recommendation Justification
.... 7.21 Recommendation Justification AWMF
.... 7.22 Recommendation Justification GRADE
.... 7.23 Artifact Contact (Extended)
.... 7.24 Author Language
.... 7.25 Consultation Period
.... 7.26 First Publication Date
.... 7.27 Guideline Author Role
.... 7.28 Planned Completion Date
.... 7.29 Publication Date
.... 7.30 Recommendation Version Status
.... 7.31 Registration Date
.... 7.32 RelatesTo Classifier
.... 7.33 RelatesTo Label
.... 7.34 Section Coding
.... 7.35 Section Intended Audience
.... 7.36 Section Keyword
.... 7.37 Section Language
.... 7.38 Submission Date
.... 7.39 AGREE II Domains Value Set
.... 7.40 AMSTAR 2 Confidence Ratings Value Set
.... 7.41 AWMF Guideline Class
.... 7.42 AWMF Guideline Status
.... 7.43 Body System Conditions
.... 7.44 Care Level
.... 7.45 CareStage
.... 7.46 Clinical Application Type
.... 7.47 Content Types
.... 7.48 Dissemination Website
.... 7.49 Encounter Type
.... 7.50 Evidence Rating System Value Set
.... 7.51 Guideline Author Role
.... 7.52 Guideline Contact Point VS
.... 7.53 Guideline Release Type
.... 7.54 Guideline Sections
.... 7.55 Intended Audience Value Set
.... 7.56 Level Of Consensus
.... 7.57 OCEBM 2011 Levels of Evidence Value Set
.... 7.58 Rating Acceptability
.... 7.59 Rating Benefits And Harms
.... 7.60 Rating Certainty Of Evidence
.... 7.61 Rating Concern Degree
.... 7.62 Rating Equity
.... 7.63 Rating Feasibility
.... 7.64 Rating Preference And Values
.... 7.65 Rating Resources
.... 7.66 Recommendation Strength (AWMF) ValueSet
.... 7.67 Recommendation Synthesis Type
.... 7.68 Recommendation Tags
.... 7.69 Recommendation Version Status Value Set
.... 7.70 Remark Type
.... 7.71 RoB2 Overall Judgment ValueSet
.... 7.72 ROBIS Judgment of Risk of Bias Value Set
.... 7.73 ROBIS Risk of Bias Domains Value Set
.... 7.74 Target Patient Group
.... 7.75 AGREE II Domains
.... 7.76 AMSTAR 2 Overall Confidence Ratings
.... 7.77 awmf
.... 7.78 AWMF Guideline Class
.... 7.79 AWMF Guideline Status
.... 7.80 Body System Conditions
.... 7.81 Care Setting
.... 7.82 Clinical Application Type
.... 7.83 Contact Point
.... 7.84 Evidence Rating System Code System
.... 7.85 Evidence To Decision Certainty Rating
.... 7.86 Evidence To Decision Certainty type
.... 7.87 Guideline Author Role
.... 7.88 Guideline Release Type
.... 7.89 Guideline Sections
.... 7.90 Intended Audience Code System
.... 7.91 Level of Consensus
.... 7.92 Medical Subject Categories
.... 7.93 OCEBM 2011 Levels of Evidence
.... 7.94 Recommendation Strength (AWMF)
.... 7.95 Recommendation Synthesis Type
.... 7.96 Recommendation Tags
.... 7.97 Recommendation Version Status Code System
.... 7.98 Related Artifact Types
.... 7.99 Remark Type
.... 7.100 RoB2 Overall Judgment
.... 7.101 ROBIS Judgment of Risk of Bias
.... 7.102 ROBIS Risk of Bias Domains
.... 7.103 Target Patient Group
.... 7.104 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)
.... 7.105 AWMF Guideline Example
.... 7.106 AWMF Guideline S1 Example
.... 7.107 AWMF Guideline S2e Example
.... 7.108 AWMF Guideline S2k Example
.... 7.109 AWMF Guideline S3 Example
.... 7.110 AWMF Member Organization Example
.... 7.111 Certainty of Evidence Rating for Multiplex-PCR-Diagnostik - Antibiotic Days
.... 7.112 Certainty of Evidence Rating for Multiplex-PCR-Diagnostik - Mortality
.... 7.113 Certainty of Evidence Rating for Multiplex-PCR-Diagnostik - Time to Deescalation
.... 7.114 Concept map from concepts from standardized vocabularies (that are not standard OMOP concepts) to Concept IDs of OMOP standard Concepts
.... 7.115 DGAI
.... 7.116 DGAI
.... 7.117 DGCH
.... 7.118 DGHM
.... 7.119 DGI
.... 7.120 DGIIN
.... 7.121 DGIM
.... 7.122 DRG
.... 7.123 DSG
.... 7.124 Evidence-Multiplex PCR Diagnostic-Antibiotic Days
.... 7.125 Evidence-Multiplex PCR Diagnostic-Mortality
.... 7.126 Evidence-Multiplex PCR Diagnostic-Time to Deescalation
.... 7.127 Foliensatz
.... 7.128 GfV
.... 7.129 Guideline Attachment Example
.... 7.130 Guideline Author Example
.... 7.131 Guideline Author Role Example
.... 7.132 Guideline Example
.... 7.133 Guideline Example
.... 7.134 Guideline Example
.... 7.135 Guideline Example
.... 7.136 Guideline Example
.... 7.137 Guideline Example
.... 7.138 Guideline Example
.... 7.139 Guideline Example
.... 7.140 Guideline Example
.... 7.141 Guideline Example
.... 7.142 Guideline Example
.... 7.143 Guideline Example
.... 7.144 Guideline Example
.... 7.145 Guideline Example
.... 7.146 Guideline Example
.... 7.147 Guideline Example
.... 7.148 Guideline Example
.... 7.149 Guideline with contributing author referencing Practitioner (fails invariant)
.... 7.150 Guideline with leading author referencing Organization (passes invariant)
.... 7.151 Guideline with leading author referencing Practitioner (fails invariant)
.... 7.152 HAP Diagnose
.... 7.153 HAP Diagnose - Empfehlung A
.... 7.154 HAP Diagnose - Empfehlung B
.... 7.155 Implementierungshilfe
.... 7.156 Jessica Rademacher
.... 7.157 Jessica Rademacher for DGP in the context of 020-013
.... 7.158 Kurzfassung
.... 7.159 Langfassung
.... 7.160 Leitlinienreport
.... 7.161 Multiplex-PCR-Diagnostik
.... 7.162 Netzwerk chronisch pulmonale Aspergillose (CPAnet)
.... 7.163 Outcome Antibiotic Days
.... 7.164 Outcome Mortality
.... 7.165 Outcome Time to Deescalation
.... 7.166 Patienteninformation
.... 7.167 PEG
.... 7.168 Recommendation Example
.... 7.169 Recommendation-PlanDefinition-example
.... 7.170 RecommendationHAPDiagnosis-A-Justification
.... 7.171 RecommendationHAPDiagnosis-B-Justification
.... 7.172 RecommendationMultiplexPCRDiagnostic-Justification
.... 7.173 Robert Koch-Institut
.... 7.174 S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie